PROTOCOL SCHEMATIC 
1. Patient screening and Informed Consent 
2. Resection of metastatic melanoma with cyropreservation of fresh tumor and attempt to 
establish cell line. 
3. Vaccination in subcutaneous sites biweekly x6 and monthly thereafter for up to 1 year 
of melanoma vaccine. Vaccine preparation: 
Autologous Tumor 
10 7 cells 
freshly cyropreserved + 
or 
melanoma cell line 
(only if sufficient fresh 
tumor not available) 
M-24 QL-21 
10 patients each in 
dose-escalation groups 
A 10 3 pg IL-2/day 
B 10 4 pg IL-2/day 
C 10 5 pg IL-2/day 
4. Treatment Evaluation 
A. Clinical response of measurable lesions 
B. Autologous tumor cell skin test with biopsy (week 0,4,8,12, then monthly for up 
to 1 year) 
C. Evaluation of peripheral PBL for CTL/LAK activity. 
\ 
[418] 
Recombinant DNA Research, Volume 18 
